晚期肝细胞癌患者对Lenvatinib和Pembrolizumab组合的完全反应：一

StephenW

BMC Cancer. 2019 Nov 8;19(1):1062. doi: 10.1186/s12885-019-6287-8.
Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report.
Liu Z1, Li X1, He X2, Xu Y3, Wang X4.
Author information

1
    Department of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, People's Republic of China.
2
    Department of Oncology, the 903rd Hospital of PLA, 14 Lingyin Road, Hangzhou, 310013, China.
3
    Department of Oncology, Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200127, People's Republic of China. [email protected].
4
    Department of Oncology, the 903rd Hospital of PLA, 14 Lingyin Road, Hangzhou, 310013, China. [email protected].

Abstract
BACKGROUND:

The majority of patients diagnosed with hepatocellular carcinoma (HCC) have advanced diseases and many are not eligible for curative therapies.
CASE PRESENTATION:

We report a rare case of HCC from a patient who had a complete response (CR) with the use of combination of Lenvatinib and Pembrolizumab. A 63-year-old man presented at the hospital with serious abdominal pain and was found to have a mass with heterogeneous enhancement and with hemorrhage in segment III of the liver after the examination of abdominal computerized tomography (CT) scan. The patient's history of viral hepatitis B infection, liver cirrhosis and the ɑ-fetoprotein (AFP) level of 14,429.3 ng/ml supported the clinical diagnosis of HCC and laboratory results demonstrated liver function damage status (Child-Pugh class B, Score 8). The patient first received hepatic arterial embolization treatment on 28th November 2017. At this stage supportive care was recommended for poor liver function. In February 2018, combined immunotherapy of Pembrolizumab (2 mg/kg, q3w) and Lenvatinib (8 mg-4 mg, qd) were performed. Nine months following the treatment he had a CR and now, 22 months since the initial treatment, there is no clinical evidence of disease progression. The current overall survival is 22 months.
CONCLUSIONS:

HCC is a potentially lethal malignant tumor and the combination of immunotherapy plus anti-angiogenic inhibitors shows promising outcome for advanced diseases.
KEYWORDS:

Hepatocellular carcinoma; Immunotherapy; Lenvatinib; Pembrolizumab

PMID:
    31703571
DOI:
    10.1186/s12885-019-6287-8

StephenW

BMC癌症。 2019十一月8; 19（1）：1062。 doi：10.1186 / s12885-019-6287-8。
晚期肝细胞癌患者对Lenvatinib和Pembrolizumab组合的完全反应：一例。
刘Z1，李X1，何X2，徐Y3，王X4。
作者信息

1个
    上海交通大学医学院附属上海仁济医院肿瘤科，上海200127
2
    杭州市灵隐路14号解放军第903医院肿瘤科，杭州310013
3
    上海交通大学医学院附属上海仁济医院肿瘤科，上海200127 [email protected]。
4
    杭州市灵隐路14号解放军第903医院肿瘤科，杭州310013 [email protected]。

抽象
背景：

大多数被诊断患有肝细胞癌（HCC）的患者患有晚期疾病，许多患者不符合治愈性治疗的条件。
案例介绍：

我们报告了使用Lenvatinib和Pembrolizumab合并完全缓解（CR）的患者发生HCC的罕见情况。一名63岁的男子在医院就诊，腹部严重疼痛，经腹部CT扫描检查后发现其肿块异质性增高，并且在肝脏的III段有出血。患者的病毒性乙型肝炎感染，肝硬化和甲胎蛋白（AFP）水平为14,429.3 ng / ml的历史支持HCC的临床诊断，实验室结果显示肝功能受损状态（Child-Pugh B级，评分8）。该患者于2017年11月28日首次接受肝动脉栓塞治疗。在此阶段，建议对肝功能不佳的患者进行支持治疗。 2018年2月，对Pembrolizumab（2μmg/ kg，q3w）和Lenvatinib（8μmg-4μmg，qd）进行了联合免疫治疗。治疗后9个月，他接受了CR，现在，自首次治疗以来已有22个月，没有临床证据表明疾病进展。目前的总生存期为22个月。
结论：

肝癌是一种潜在的致命恶性肿瘤，免疫疗法与抗血管生成抑制剂的组合显示出对晚期疾病有希望的结果。
关键字：

肝细胞癌；免疫疗法伦伐替尼;派姆单抗

PMID：
    31703571
DOI：
    10.1186 / s12885-019-6287-8

StephenW

https://bmccancer.biomedcentral. ... 6/s12885-019-6287-8